<p>Exelixis（纳斯达克股票代码：EXEL）将于 2026 年 2 月 10 日发布季度财报。以下是投资者在公告前的简要概述。</p>
<p>分析师预计 Exelixis 的 <strong>每股收益</strong>（EPS）为 0.76 美元。</p>
<p>市场期待 Exelixis 的公告，寄希望于超出预期的消息，并为下个季度提供乐观的指引。</p>
<p>新投资者需要理解，指引可能是股价的重要驱动因素。</p>
<h3>财报历史快照</h3>
<p>该公司在上个季度的每股收益超出预期 0.15 美元，导致次日股价上涨 6.52%。</p>
<p>以下是 Exelixis 的过去表现及其相应的价格变化：</p>
<table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
<th align="right"><strong>2024 年第四季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 预估</strong></td>
<td align="right">0.63</td>
<td align="right">0.61</td>
<td align="right">0.44</td>
<td align="right">0.49</td>
</tr>
<tr>
<td><strong>EPS 实际</strong></td>
<td align="right">0.78</td>
<td align="right">0.75</td>
<td align="right">0.62</td>
<td align="right">0.55</td>
</tr>
<tr>
<td><strong>价格变化 %</strong></td>
<td align="right">7.00</td>
<td align="right">-17.00</td>
<td align="right">21.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770656505_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="eps graph" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770656505_0.png"/></p>
<h3>Exelixis 股价分析</h3>
<p>截至 2 月 6 日，Exelixis 的股价为 43.9 美元。在过去 52 周内，股价上涨了 33.59%。鉴于这些回报通常是积极的，长期股东在此次财报发布前可能持乐观态度。</p>
<h3>分析师对 Exelixis 的看法</h3>
<p>了解市场情绪和行业内的预期对投资者至关重要。此分析深入探讨了关于 Exelixis 的最新见解。</p>
<p>Exelixis 的共识评级为买入，基于 6 位分析师的评级。平均一年目标价为 49.5 美元，潜在上涨空间为 12.76%。</p>
<h3>同业评级比较</h3>
<p>以下分析聚焦于 Exelixis 及 BioMarin Pharmaceutical 这三家知名行业公司的分析师评级和平均一年目标价，提供对其相对表现预期和市场定位的见解。</p>
<ul>
<li>分析师目前对 BioMarin Pharmaceutical 的评级为买入，平均一年目标价为 80.4 美元，暗示潜在上涨空间为 83.14%。</li>
</ul>
<h3>同业指标摘要</h3>
<p>在同业分析摘要中，展示了 Exelixis 及 BioMarin Pharmaceutical 的重要指标，揭示了它们在行业中的相对地位，并提供了对其市场位置和比较表现的有价值见解。</p>
<table>
<thead>
<tr>
<th>公司</th>
<th>共识</th>
<th>收入增长</th>
<th>毛利润</th>
<th>股本回报率</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exelixis</td>
<td>买入</td>
<td>10.79%</td>
<td>5.7918 亿美元</td>
<td>9.23%</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical</td>
<td>买入</td>
<td>4.08%</td>
<td>6.3605 亿美元</td>
<td>-0.51%</td>
</tr>
</tbody>
</table>
<p>关键要点：</p>
<p>Exelixis 在收入增长和毛利润方面高于其同行。然而，其股本回报率低于同行。</p>
<h3>关于 Exelixis 的所有信息</h3>
<p>Exelixis Inc 是一家生物制药公司，专注于发现、开发和商业化癌症治疗方案。其分子 cabozantinib 被用于治疗转移性髓样甲状腺癌，商品名为 Cometriq，并用于治疗肾癌和肝癌，商品名为 Cabometyx。Exelixis 及其合作伙伴罗氏还推出了 Cotellic 用于黑色素瘤的治疗。</p>
<h3>财务洞察：Exelixis</h3>
<p><strong>市值：</strong> 由于市值受限，该公司在行业平均水平以下。这反映出其相对于同行的规模较小。</p>
<p><strong>收入增长：</strong> Exelixis 在过去 3 个月的收入增长显著。截至 2025 年 9 月 30 日，该公司的收入增长率约为 <strong>10.79%</strong>。这表明公司的营业收入有了显著增加。与行业同行相比，该公司的增长率低于医疗保健行业的平均水平。</p>
<p><strong>净利润率：</strong> Exelixis 的财务实力体现在其卓越的净利润率上，超过行业平均水平。该公司的净利润率达到 <strong>32.38%</strong>，展现出强劲的盈利能力和有效的成本管理。</p>
<p><strong>股本回报率（ROE）：</strong> Exelixis 的财务实力体现在其卓越的 ROE 上，超过行业平均水平。该公司的 ROE 达到 <strong>9.23%</strong>，展现出对股本资本的高效利用和强健的财务健康。</p>
<p><strong>资产回报率（ROA）：</strong> Exelixis 的 ROA 超过行业标准，突显出公司的卓越财务表现。该公司的 ROA 达到 <strong>7.04%</strong>，有效利用资产以获得最佳回报。</p>
<p><strong>债务管理：</strong> Exelixis 的债务与股本比率低于行业平均水平。该比率为 <strong>0.08</strong>，公司较少依赖债务融资，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极的信号。</p>
<p>要跟踪 Exelixis 的所有财报发布，请访问我们网站的财报日历。</p>
<p><em>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</em></p>

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

标普全球医疗股指数 ETF - iShares

<p>Exelixis（纳斯达克代码：EXEL）定于 2026 年 2 月 10 日发布季度财报，分析师预计每股收益（EPS）为 0.76 美元。该公司表现积极，上个季度超出 EPS 预期，导致股价上涨 6.52%。目前股价为 43.9 美元，过去一年上涨了 33.59%。分析师对该股票给予 “买入” 评级，目标价为 49.5 美元，显示出潜在的上涨空间。与同行相比，Exelixis 在收入增长和净利润率方面表现出色，展现出强劲的财务健康状况</p>

<p>Exelixis (NASDAQ: EXEL) will release its quarterly earnings report on Tuesday, 2026-02-10. Here's a brief overview for investors ahead of the announcement.</p>
<div class="lb-trans"><p>Exelixis（纳斯达克股票代码：EXEL）将于 2026 年 2 月 10 日发布季度财报。以下是投资者在公告前的简要概述。</p>
</div><p>Analysts anticipate Exelixis to report an <strong>earnings per share</strong> (EPS) of $0.76.</p>
<div class="lb-trans"><p>分析师预计 Exelixis 的 <strong>每股收益</strong>（EPS）为 0.76 美元。</p>
</div><p>The market awaits Exelixis's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<div class="lb-trans"><p>市场期待 Exelixis 的公告，寄希望于超出预期的消息，并为下个季度提供乐观的指引。</p>
</div><p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<div class="lb-trans"><p>新投资者需要理解，指引可能是股价的重要驱动因素。</p>
</div><h3>Earnings History Snapshot</h3>
<div class="lb-trans"><h3>财报历史快照</h3>
</div><p>The company's EPS beat by $0.15 in the last quarter, leading to a 6.52% increase in the share price on the following day.</p>
<div class="lb-trans"><p>该公司在上个季度的每股收益超出预期 0.15 美元，导致次日股价上涨 6.52%。</p>
</div><p>Here's a look at Exelixis's past performance and the resulting price change:</p>
<div class="lb-trans"><p>以下是 Exelixis 的过去表现及其相应的价格变化：</p>
</div><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q3 2025</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">0.63</td>
<td align="right">0.61</td>
<td align="right">0.44</td>
<td align="right">0.49</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">0.78</td>
<td align="right">0.75</td>
<td align="right">0.62</td>
<td align="right">0.55</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">7.00</td>
<td align="right">-17.00</td>
<td align="right">21.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
<th align="right"><strong>2024 年第四季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 预估</strong></td>
<td align="right">0.63</td>
<td align="right">0.61</td>
<td align="right">0.44</td>
<td align="right">0.49</td>
</tr>
<tr>
<td><strong>EPS 实际</strong></td>
<td align="right">0.78</td>
<td align="right">0.75</td>
<td align="right">0.62</td>
<td align="right">0.55</td>
</tr>
<tr>
<td><strong>价格变化 %</strong></td>
<td align="right">7.00</td>
<td align="right">-17.00</td>
<td align="right">21.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770656505_0.png" alt="eps graph" original-src="https://www.benzinga.com/files/images/story/2026/1770656505_0.png"/></p>
<h3>Exelixis Share Price Analysis</h3>
<div class="lb-trans"><h3>Exelixis 股价分析</h3>
</div><p>Shares of Exelixis were trading at $43.9 as of February 06. Over the last 52-week period, shares are up 33.59%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.</p>
<div class="lb-trans"><p>截至 2 月 6 日，Exelixis 的股价为 43.9 美元。在过去 52 周内，股价上涨了 33.59%。鉴于这些回报通常是积极的，长期股东在此次财报发布前可能持乐观态度。</p>
</div><h3>Analysts' Perspectives on Exelixis</h3>
<div class="lb-trans"><h3>分析师对 Exelixis 的看法</h3>
</div><p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Exelixis.</p>
<div class="lb-trans"><p>了解市场情绪和行业内的预期对投资者至关重要。此分析深入探讨了关于 Exelixis 的最新见解。</p>
</div><p>The consensus rating for Exelixis is Buy, based on 6 analyst ratings. With an average one-year price target of $49.5, there's a potential 12.76% upside.</p>
<div class="lb-trans"><p>Exelixis 的共识评级为买入，基于 6 位分析师的评级。平均一年目标价为 49.5 美元，潜在上涨空间为 12.76%。</p>
</div><h3>Peer Ratings Comparison</h3>
<div class="lb-trans"><h3>同业评级比较</h3>
</div><p>The following analysis focuses on the analyst ratings and average 1-year price targets of and BioMarin Pharmaceutical, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<div class="lb-trans"><p>以下分析聚焦于 Exelixis 及 BioMarin Pharmaceutical 这三家知名行业公司的分析师评级和平均一年目标价，提供对其相对表现预期和市场定位的见解。</p>
</div><ul>
<li>Analysts currently favor an Buy trajectory for BioMarin Pharmaceutical, with an average 1-year price target of $80.4, suggesting a potential 83.14% upside.</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师目前对 BioMarin Pharmaceutical 的评级为买入，平均一年目标价为 80.4 美元，暗示潜在上涨空间为 83.14%。</li>
</ul>
</div><h3>Peer Metrics Summary</h3>
<div class="lb-trans"><h3>同业指标摘要</h3>
</div><p>Within the peer analysis summary, vital metrics for and BioMarin Pharmaceutical are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<div class="lb-trans"><p>在同业分析摘要中，展示了 Exelixis 及 BioMarin Pharmaceutical 的重要指标，揭示了它们在行业中的相对地位，并提供了对其市场位置和比较表现的有价值见解。</p>
</div><table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exelixis</td>
<td>Buy</td>
<td>10.79%</td>
<td>$579.18M</td>
<td>9.23%</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical</td>
<td>Buy</td>
<td>4.08%</td>
<td>$636.05M</td>
<td>-0.51%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>公司</th>
<th>共识</th>
<th>收入增长</th>
<th>毛利润</th>
<th>股本回报率</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exelixis</td>
<td>买入</td>
<td>10.79%</td>
<td>5.7918 亿美元</td>
<td>9.23%</td>
</tr>
<tr>
<td>BioMarin Pharmaceutical</td>
<td>买入</td>
<td>4.08%</td>
<td>6.3605 亿美元</td>
<td>-0.51%</td>
</tr>
</tbody>
</table>
</div><p>Key Takeaway:</p>
<div class="lb-trans"><p>关键要点：</p>
</div><p>Exelixis ranks higher than its peers in terms of revenue growth and gross profit. However, it has a lower return on equity compared to its peers.</p>
<div class="lb-trans"><p>Exelixis 在收入增长和毛利润方面高于其同行。然而，其股本回报率低于同行。</p>
</div><h3>All You Need to Know About Exelixis</h3>
<div class="lb-trans"><h3>关于 Exelixis 的所有信息</h3>
</div><p>Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.</p>
<div class="lb-trans"><p>Exelixis Inc 是一家生物制药公司，专注于发现、开发和商业化癌症治疗方案。其分子 cabozantinib 被用于治疗转移性髓样甲状腺癌，商品名为 Cometriq，并用于治疗肾癌和肝癌，商品名为 Cabometyx。Exelixis 及其合作伙伴罗氏还推出了 Cotellic 用于黑色素瘤的治疗。</p>
</div><h3>Financial Insights: Exelixis</h3>
<div class="lb-trans"><h3>财务洞察：Exelixis</h3>
</div><p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<div class="lb-trans"><p><strong>市值：</strong> 由于市值受限，该公司在行业平均水平以下。这反映出其相对于同行的规模较小。</p>
</div><p><strong>Revenue Growth:</strong> Exelixis's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately <strong>10.79%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Exelixis 在过去 3 个月的收入增长显著。截至 2025 年 9 月 30 日，该公司的收入增长率约为 <strong>10.79%</strong>。这表明公司的营业收入有了显著增加。与行业同行相比，该公司的增长率低于医疗保健行业的平均水平。</p>
</div><p><strong>Net Margin:</strong> Exelixis's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>32.38%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Exelixis 的财务实力体现在其卓越的净利润率上，超过行业平均水平。该公司的净利润率达到 <strong>32.38%</strong>，展现出强劲的盈利能力和有效的成本管理。</p>
</div><p><strong>Return on Equity (ROE):</strong> Exelixis's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>9.23%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Exelixis 的财务实力体现在其卓越的 ROE 上，超过行业平均水平。该公司的 ROE 达到 <strong>9.23%</strong>，展现出对股本资本的高效利用和强健的财务健康。</p>
</div><p><strong>Return on Assets (ROA):</strong> Exelixis's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.04%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Exelixis 的 ROA 超过行业标准，突显出公司的卓越财务表现。该公司的 ROA 达到 <strong>7.04%</strong>，有效利用资产以获得最佳回报。</p>
</div><p><strong>Debt Management:</strong> Exelixis's debt-to-equity ratio is below the industry average. With a ratio of <strong>0.08</strong>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Exelixis 的债务与股本比率低于行业平均水平。该比率为 <strong>0.08</strong>，公司较少依赖债务融资，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极的信号。</p>
</div><p>To track all earnings releases for Exelixis visit their earnings calendar on our site.</p>
<div class="lb-trans"><p>要跟踪 Exelixis 的所有财报发布，请访问我们网站的财报日历。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</em></p>
</div>

伊克力西斯未来收益展望